EGFR and non-small cell lung carcinoma: Combination of HDACi vorinostat and erlotinib was investigated in a phase I/II clinical trial, where it demonstrated a favorable toxicity profile but failed to provide survival benefit in EGFR-mutant NSCLC patients with prior progression on erlotinib (Reguart et al., 2014).